Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: A systematic review and meta-analysis

Leukemia Research

Volumn 38, Issue 4, 2014, Pages 460-468

  Oberoi, Sapna ^a   Lehrnbecher, Thomas ^b   Phillips, Bob ^c,d   Hitzler, Johann ^a   Ethier, Marie Chantal ^a   Beyene, Joseph ^a,e   Sung, Lillian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b GOETHE UNIVERSITY   (Germany)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Acute myeloid leukemia; Early deaths; Hydroxyurea; Leukapheresis; Leukostasis

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; MITOXANTRONE; PREDNISONE; PYRIMETHAMINE; RETINOIC ACID; TIOGUANINE; TOPOTECAN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER MORTALITY; EXCHANGE BLOOD TRANSFUSION; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKAPHERESIS; LEUKOCYTE COUNT; LEUKOSTASIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW;

ACUTE MYELOID LEUKEMIA; EARLY DEATHS; HYDROXYUREA; LEUKAPHERESIS; LEUKOSTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKAPHERESIS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897108505     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.01.004     Document Type: Article

References (40)

1. Fischer M.J., Rheingold S.R. Oncologic emergencies. Principles and practices of pediatric oncology 2011, 1125-1151. Lippencott Williams and Wilkins, Philadelphia. 6th ed. P.A. Pizzo, D.G. Poplack (Eds.).
2. Porcu P., Cripe L.D., Ng E.W., Bhatia S., Danielson C.M., Orazi A., et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000, 39:1-18.
3. Hug V., Keating M., McCredie K., Hester J., Bodey G.P., Freireich E.J. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 1983, 52:773-779.
4. Creutzig U., Ritter J., Budde M., Sutor A., Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987, 60:3071-3079.
5. Sung L., Aplenc R., Alonzo T.A., Gerbing R.B., Gamis A.S. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica 2012, 97:1770-1773.
6. Slats A.M., Egeler R.M., van der Does-van den Berg A., Korbijn C., Hahlen K., Kamps W.A., et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005, 19:537-544.
7. Dutcher J.P., Schiffer C.A., Wiernik P.H. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987, 5:1364-1372.
8. Inaba H., Khan R.B., Laningham F.H., Crews K.R., Pui C.H., Daw N.C. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008, 19:178-184.
9. Porcu P., Danielson C.F., Orazi A., Heerema N.A., Gabig T.G., McCarthy L.J. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997, 98:433-436.
10. Lichtman M.A., Rowe J.M. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 1982, 60:279-283.
11. McKee L.C., Collins R.D. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimore) 1974, 53:463-478.
12. Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001, 97:2121-2129.
13. Howard S.C., Jones D.P., Pui C.H. The tumor lysis syndrome. N Engl J Med 2011, 364:1844-1854.
14. Giles F.J., Shen Y., Kantarjian H.M., Korbling M.J., O'Brien S., Anderlini P., et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival. Leuk Lymphoma 2001, 42:67-73.
15. Creutzig U., Zimmermann M., Reinhardt D., Dworzak M., Stary J., Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004, 22:4384-4393.
16. Chang M.C., Chen T.Y., Tang J.L., Lan Y.J., Chao T.Y., Chiu C.F., et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol 2007, 82:976-980.
17. Liang R., Bai Q.X., Zhang Y.Q., Zhang T., Yang L., Wang Y.W., et al. Reduced tumor lysis syndrome with low dose chemotherapy for hyperleukocytic acute leukemia prior to induction therapy. Asian Pac J Cancer Prev 2011, 12:1807-1811.
18. Greenwood M.J., Seftel M.D., Richardson C., Barbaric D., Barnett M.J., Bruyere H., et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 2006, 47:1245-1252.
19. Bug G., Anargyrou K., Tonn T., Bialleck H., Seifried E., Hoelzer D., et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion 2007, 47:1843-1850.
20. Ventura G.J., Hester J.P., Smith T.L., Keating M.J. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988, 27:34-37.
21. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
22. Hayden J.A., Cote P., Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006, 144:427-437.
23. Bieler G.S., Williams R.L. Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity. Biometrics 1993, 49:793-801.
24. Sterne J.A.C., Egger M., Moher D. Chapter 10: addressing reporting biases. Cochrane handbook for systematic reviews of interventions version 501 [updated September 2008] The Cochrane Collaboration 2008, Available from www.cochrane-handbook.org (accessed 01.07.13). J.P.T. Higgins, S. Green (Eds.).
25. Bosly A., Sonet A., Pinkerton C.R., McCowage G., Bron D., Sanz M.A., et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003, 98:1048-1054.
26. Pui C.H., Mahmoud H.H., Wiley J.M., Woods G.M., Leverger G., Camitta B., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001, 19:697-704.
27. Kikuchi A., Kigasawa H., Tsurusawa M., Kawa K., Kikuta A., Tsuchida M., et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol 2009, 90:492-500.
28. De Bernardi B., Pianca C., Pistamiglio P., Veneselli E., Viscardi E., Pession A., et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 2001, 19:183-190.
29. Matsubara H., Watanabe K., Sakai H., Chang H., Fujino H., Higashi Y., et al. Rapid improvement of paraplegia caused by epidural involvements of Burkitt's lymphoma with chemotherapy. Spine (Philadelphia, PA, 1976) 2004, 29:E4-E6.
30. Buchta C., Macher M., Bieglmayer C., Hocker P., Dettke M. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion 2003, 43:1615-1621.
31. Schlenke P., Frohn C., Steinhardt M.M., Kirchner H., Kluter H. Clinically relevant hypokalaemia, hypocalcaemia, and loss of hemoglobin and platelets during stem cell apheresis. J Clin Apheresis 2000, 15:230-235.
32. Vahdat L., Maslak P., Miller W.H., Eardley A., Heller G., Scheinberg D.A., et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994, 84:3843-3849.
33. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
34. Molgaard-Hansen L., Mottonen M., Glosli H., Jonmundsson G.K., Abrahamsson J., Hasle H. Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. Br J Haematol 2010, 151:447-459.
35. Marbello L., Ricci F., Nosari A.M., Turrini M., Nador G., Nichelatti M., et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res 2008, 32:1221-1227.
36. Tan D., Hwang W., Goh Y.T. Therapeutic leukapheresis in hyperleukocytic leukaemias-the experience of a tertiary institution in Singapore. Ann Acad Med Singapore 2005, 34:229-234.
37. Thiebaut A., Thomas X., Belhabri A., Anglaret B., Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000, 79:501-506.
38. Bunin N.J., Pui C.H. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985, 3:1590-1595.
39. Cuttner J., Holland J.F., Norton L., Ambinder E., Button G., Meyer R.J. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. Med Pediatr Oncol 1983, 11:76-78.
40. Reiffers J., Raynal F., Broustet A. Acute myeloblastic leukemia in elderly patients: treatment and prognostic factors. Cancer 1980, 45:2816-2820.